




[12] Patent

[11] Patent No.: GC 0000248	Number of the Decision to Grant the Patent: 6/876
[45] Date of Publishing the Grant of the Patent: 01/11/2006 6/2006	Date of the Decision to Grant the Patent: 18/06/2006
[21] Application No.: GCC/P/2000/481 [22] Filing Date: 17/01/2000 [30] Priority: [31] Priority No. [32] Priority date [33] State 99100784.0 18/01/1999 EP [72] Inventors: 1- Volker Breu, 2- Philippe Coassolo, 3- Rolf Huber, 4- Werner Neidhart, 5- Henri Ramuz, 6- Sebastien Roux, 7- Hans Peter Wessel [73] Owner: F. Hoffmann – La Roche AG, 124 Grenzacherstrasse, CH-4070 Basle, Switzerland [74] Agent: Nassir Ali Kadasa	[51] Int. Cl. ⁷ : C07D 401/12, 401/14, 413/14, 417/12; A61K 31/505; A61P 9/00 [56] Cited Documents: - EP 0713875 A (F. HOFFMANN-LA ROCHE AG) 29 May 1996 - WO 9619459 A (F. HOFFMANN-LA ROCHE AG) 27 June 1996 - WO 9722595 A (YAMANOUCHI PHARMACEUTICAL CO., LTD.) 26 June 1997 - "A New Hydrosoluble Endothelin Antagonist: General Pharmacology and Effects on Experimental Cerebral Vasospasm" (S. ROUX et al.) Ro 61-1790, J. PHARMACOL. EXP. THER., Vol 283, No. 3, 1997

[54] NOVEL HETEROCYCLIC SULFONAMIDES

[57] Abstract: The compounds of formula (I)



wherein R¹, R² and X have the significance as given in the description, are inhibitors of endothelin receptors and can therefore be used for the treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction.

No. of claims: 18